Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18064332rdf:typepubmed:Citationlld:pubmed
pubmed-article:18064332lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:18064332lifeskim:mentionsumls-concept:C0040053lld:lifeskim
pubmed-article:18064332lifeskim:mentionsumls-concept:C0038257lld:lifeskim
pubmed-article:18064332lifeskim:mentionsumls-concept:C0255567lld:lifeskim
pubmed-article:18064332lifeskim:mentionsumls-concept:C0237881lld:lifeskim
pubmed-article:18064332lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:18064332lifeskim:mentionsumls-concept:C1514983lld:lifeskim
pubmed-article:18064332pubmed:issue6lld:pubmed
pubmed-article:18064332pubmed:dateCreated2007-12-7lld:pubmed
pubmed-article:18064332pubmed:abstractTextLow-response to the P2Y12 adenosine diphosphate (ADP)-receptor antagonist clopidogrel was suggested to correspond to a higher incidence of stent thrombosis (ST). This prospective observational study assessed the capability of two platelet function assays, e.g. direct measurement of the phosphorylation status of vasodilator-stimulated phosphoprotein (VASP) and ADP-induced platelet aggregation for definition of the individual risk to develop ST. Ninety-nine patients with an elevated high risk to develop ST were enrolled. All patients received a dual antiplatelet therapy consisting of 100 mg aspirin and 75 mg clopidogrel during an observation period of six months. Flow cytometry of VASP phosphorylation and densitometrically-determined measurement of ADP-induced platelet aggregation was performed 72-96 hours after stent implantation. These data were related to angiographically confirmed ST. Nine patients suffered from angiographically confirmed ST (9.1%). The meanVASP-platelet reactivity indices (VASP-PRI) and values for ADP-induced platelet aggregation in the ST group were significantly higher (60.8 +/- 13.0 and 60.9 +/- 13.1, respectively) compared to patients without ST (41.3 +/- 14.0 and 50.8 +/- 14.4, P < 0.001 vs. 0.048, respectively). There was a fair correlation between both methods using non-linear regression analysis (r = 0.332). In a multivariate analysis, VASP was the only independent predictor of ST and was superior to previously identified angiographic parameters. Receiver- operator characteristic (ROC) curve analysis revealed a cut-off value for VASP-PRI of <48% to be associated with low risk of ST. In conclusion, determination of VASP phosphorylation is superior to conventional platelet aggregometry and angiographic parameters for assessing the risk of ST. Patients with a VASP-PRI >48% seem to have a significantly increased risk.lld:pubmed
pubmed-article:18064332pubmed:languageenglld:pubmed
pubmed-article:18064332pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:citationSubsetIMlld:pubmed
pubmed-article:18064332pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18064332pubmed:statusMEDLINElld:pubmed
pubmed-article:18064332pubmed:monthDeclld:pubmed
pubmed-article:18064332pubmed:issn0340-6245lld:pubmed
pubmed-article:18064332pubmed:authorpubmed-author:KelmMalteMlld:pubmed
pubmed-article:18064332pubmed:authorpubmed-author:WeberChristia...lld:pubmed
pubmed-article:18064332pubmed:authorpubmed-author:HoffmannRaine...lld:pubmed
pubmed-article:18064332pubmed:authorpubmed-author:KieferPaulPlld:pubmed
pubmed-article:18064332pubmed:authorpubmed-author:BlindtRüdiger...lld:pubmed
pubmed-article:18064332pubmed:authorpubmed-author:MüllerRobertRlld:pubmed
pubmed-article:18064332pubmed:authorpubmed-author:YagmurErayElld:pubmed
pubmed-article:18064332pubmed:authorpubmed-author:StellbrinkKat...lld:pubmed
pubmed-article:18064332pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:18064332pubmed:issnTypePrintlld:pubmed
pubmed-article:18064332pubmed:volume98lld:pubmed
pubmed-article:18064332pubmed:ownerNLMlld:pubmed
pubmed-article:18064332pubmed:authorsCompleteYlld:pubmed
pubmed-article:18064332pubmed:pagination1329-34lld:pubmed
pubmed-article:18064332pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:meshHeadingpubmed-meshheading:18064332...lld:pubmed
pubmed-article:18064332pubmed:year2007lld:pubmed
pubmed-article:18064332pubmed:articleTitleThe significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.lld:pubmed
pubmed-article:18064332pubmed:affiliationDepartment of Cardiology, University Hospital Aachen, Pauwelsstr. 30, 52074 Aachen, Germany. ruediger.blindt@post.rwth-aachen.delld:pubmed
pubmed-article:18064332pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18064332pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:18064332pubmed:publicationTypeComparative Studylld:pubmed
entrez-gene:7408entrezgene:pubmedpubmed-article:18064332lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18064332lld:entrezgene
lhgdn:association:27380lhgdn:found_inpubmed-article:18064332lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18064332lld:pubmed